Wound Management News

In this Healio video exclusive, George Martin, MD, discusses highlights from Maui Derm NP+PA, including a new wound healing matrix, which he said improves healing and reduces infection rates.

Diacerein 1% ointment was comparable to vehicle in study endpoints but did outperform vehicle when stratified by disease severity in the treatment of patients with epidermolysis bullosa simplex, according to a study.

The FDA has approved Avita Medical’s premarket approval supplement for the use of its Recell System for the treatment of full-thickness skin defects, according to a press release.

The VeriCyn Wound Wash medical device by Armis Biopharma has received 510(k) clearance from the FDA for use in cleansing wounds of debris, according to a company press release.

Considering the unique characteristics of different skin substitutes will provide improved wound care management that meets patient needs, according to a study.

The FDA has approved Vyjuvek (beremagene geperpavec-svdt), an investigational non-invasive, topical, redosable gene therapy for the treatment of dystrophic epidermolysis bullosa, Krystal Biotech announced in a press release.

A number of interventions and therapeutic combinations are available to treat scarring and dyschromias in individuals with Fitzpatrick skin type IV to VI, or “skin of color,” according to a study.

MIAMI BEACH, Fla. — Although they should never be injected, exosomes could change the way dermatologists heal the skin, according to a speaker at South Beach Symposium.

Patients with keloids and hypertrophic scarring were at a higher risk of developing atopic eczema, in addition to other comorbidities, across three major ethnic groups, according to a study.

Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with the general population, according to a cohort study.